Bausch + Lomb Receives 510(k) Clearance for Crystalsert 2.6 Injector for Crystalens AO and Trulign Toric IOLs

Source: Bausch + Lomb

Tuesday, January 02, 2018 | FDA Approval/Clearance , Bausch+Lomb


Bausch + Lomb announced that it has received 510(k) clearance from the FDA for the Crystalsert 2.6 injector (CI-26). Designed exclusively for use across the entire diopter range of Crystalens AO and Trulign toric IOLs, the CI-26 facilitates smooth and easy delivery through an incision as small as 2.6 mm, according to Bausch + Lomb.

“The CI-26 Injector includes several enhancements designed to assist IOL delivery through a smaller incision,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in a company news release. “Surgeons already know the benefits of our Crystalens accommodating and Trulign toric lenses, and we are happy to provide them with a smaller incision option to deliver these benefits to their patients.

The CI-26 features a smooth, oval tip shape, which allows for easy wound entry and helps prevent tissue snagging. The tip also features a straight delivery channel to reach the capsular bag without wound stretch. A haptic guide and modified plunger tip support the leading and trailing haptics during delivery. 

“As a surgeon who relies heavily on the Crystalens and Trulign IOLs, I’m looking forward to having an injector for these lenses that enables smaller incision surgery while providing smooth wound entry during implantation,” said Mitchell Shultz, MD, cataract, cornea, and refractive surgeon, from Shultz Chang Vision in Los Angeles. 


Comments

You must be logged in to leave a comment.